SCHEMBL5804479

SCHEMBL5804479

O=c1c2ncn(Cc3ccccc3)c2nc2n(Cc3ccccc3)c(-c3ccc(Cl)cc3)cn12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.45
PNP P00491 1/20 0.45
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
USP2 O75604 1/20 0.43
YTHDC1 Q96MU7 1/20 0.42
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CDK1 P06493 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
DAPK1 P53355 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6522309 0.70 PNP (0.52) PNPCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL5783265 0.69 TSHR (0.39) PNPCYP1A2CYP3A4USP2ALDH1A1
SCHEMBL1753320 0.67 CNR1 (0.44) CNR1PNPYTHDC1PDE4AKDM4E
SCHEMBL8165314 0.66 PNP (0.56) PNPCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL8076818 0.65 PNP (0.55) PNPCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL12786350 0.65 YTHDC1 (0.69) PNPYTHDC1CDK1PDE4APDE4B
SCHEMBL6272417 0.65 ALDH1A1 (0.66) PNPCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL17401396 0.65 ENPP2 (0.67)
SCHEMBL183057 0.65 YTHDC1 (0.68) PNPCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL30898278 0.65 YTHDC1 (0.68) PNPCYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270008-B1 Fused tricyclic analogues of guanosine for treating tumors YUNG SHIN PHARMACEUTICAL IND (TW) 2006-07-12 EP disclosed
US-6887997-B2 9H-imidazo[1,2-a]purin-9-one compounds YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) 2005-05-03 US disclosed
US-20030105116-A1 Fused tri-heterocyclic compounds YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) 2003-06-05 US disclosed
EP-1270008-A2 Fused tricyclic analogues of guanosine for treating tumors Yung Shin Pharmaceutical Ind. Co., Ltd. (TW) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105116-A1 Fused tri-heterocyclic compounds NR2E1, REL, RER1 CNR1 54/4885PNP 3405/4885CYP1A2 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.